Immunomodulatory drugs may overcome the negative prognostic role of active Th17 axis in follicular lymphoma: evidence from the SAKK35/10 trial
Gespeichert in:
| Veröffentlicht in: | British journal of haematology 2020-08, Vol.190 (4), p.e258-e261 |
|---|---|
| Hauptverfasser: | , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | e261 |
|---|---|
| container_issue | 4 |
| container_start_page | e258 |
| container_title | British journal of haematology |
| container_volume | 190 |
| creator | Menter, Thomas Hayoz, Stefanie Zucca, Emanuele Kimby, Eva Dirnhofer, Stefan Tzankov, Alexandar |
| description | |
| doi_str_mv | 10.1111/bjh.16876 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_swepu</sourceid><recordid>TN_cdi_swepub_primary_oai_swepub_ki_se_470594</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2412208629</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4926-c84544b023d1a2768f592ec42b4feb773b43690d4a49aa0e5575ca738136ec113</originalsourceid><addsrcrecordid>eNp1kctuEzEUhi0EoqGw4AWQJTawmMbXubArFdDSSiwoa8vjOZM42OPUnkmZl-CZcZPQBRI-C1vHnz75-EfoNSVnNK9lu1mf0bKuyidoQXkpC0YFfYoWhJCqoETUJ-hFShtCKCeSPkcnnMlcnC3Q7yvvpyH40E1OjyHOuIvTKmGvZxx2EE3wgMc14AFWerQ7wNsYVkNIozU4Bgc49Fib_c3tmlZY_7IJ2wH3wTlrsjRiN_vtOnj9AcPOdjAYwH0Mfq_9fn59zeWSEjxGq91L9KzXLsGr436Kfnz-dHtxWdx8-3J1cX5TGNGwsjC1kEK0hPGOalaVdS8bBkawVvTQVhVvBS8b0gktGq0JSFlJoyte598BQyk_RcXBm-5hO7VqG63XcVZBW3Vs_cwnUKIishGZf3fg8_R3E6RReZsMOKcHCFNSTFDGSF2yJqNv_0E3YYpDniZTXAhaUfFAvT9QJoaUIvSPT6BEPYSqcqhqH2pm3xyNU-uheyT_ppiB5QG4tw7m_5vUx6-XB-UfA_erUA</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2434417149</pqid></control><display><type>article</type><title>Immunomodulatory drugs may overcome the negative prognostic role of active Th17 axis in follicular lymphoma: evidence from the SAKK35/10 trial</title><source>MEDLINE</source><source>Wiley Free Content</source><source>Wiley Online Library All Journals</source><creator>Menter, Thomas ; Hayoz, Stefanie ; Zucca, Emanuele ; Kimby, Eva ; Dirnhofer, Stefan ; Tzankov, Alexandar</creator><creatorcontrib>Menter, Thomas ; Hayoz, Stefanie ; Zucca, Emanuele ; Kimby, Eva ; Dirnhofer, Stefan ; Tzankov, Alexandar</creatorcontrib><identifier>ISSN: 0007-1048</identifier><identifier>EISSN: 1365-2141</identifier><identifier>DOI: 10.1111/bjh.16876</identifier><identifier>PMID: 32525232</identifier><language>eng</language><publisher>England: Blackwell Publishing Ltd</publisher><subject>CD4-CD8 Ratio ; follicular lymphoma ; Gene Expression Profiling ; Helper cells ; Hematology ; Humans ; Immunologic Factors - administration & dosage ; Immunomodulation ; Kaplan-Meier Estimate ; lenalidomide ; Lenalidomide - administration & dosage ; Lymphocytes T ; Lymphoma ; Lymphoma, Follicular - drug therapy ; Lymphoma, Follicular - genetics ; Lymphoma, Follicular - mortality ; Neoplasm Proteins - biosynthesis ; Neoplasm Proteins - genetics ; Prognosis ; Progression-Free Survival ; Randomized Controlled Trials as Topic - statistics & numerical data ; Rituximab - administration & dosage ; RORγt ; Th17 Cells - immunology ; Th17 T cells ; Tumor Microenvironment</subject><ispartof>British journal of haematology, 2020-08, Vol.190 (4), p.e258-e261</ispartof><rights>2020 British Society for Haematology and John Wiley & Sons Ltd</rights><rights>Copyright © 2020 John Wiley & Sons Ltd</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c4926-c84544b023d1a2768f592ec42b4feb773b43690d4a49aa0e5575ca738136ec113</citedby><cites>FETCH-LOGICAL-c4926-c84544b023d1a2768f592ec42b4feb773b43690d4a49aa0e5575ca738136ec113</cites><orcidid>0000-0003-3078-6131 ; 0000-0002-1100-3819 ; 0000-0002-0847-6156</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1111%2Fbjh.16876$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1111%2Fbjh.16876$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>230,314,780,784,885,1416,1432,27923,27924,45573,45574,46408,46832</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/32525232$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink><backlink>$$Uhttp://kipublications.ki.se/Default.aspx?queryparsed=id:143933933$$DView record from Swedish Publication Index$$Hfree_for_read</backlink></links><search><creatorcontrib>Menter, Thomas</creatorcontrib><creatorcontrib>Hayoz, Stefanie</creatorcontrib><creatorcontrib>Zucca, Emanuele</creatorcontrib><creatorcontrib>Kimby, Eva</creatorcontrib><creatorcontrib>Dirnhofer, Stefan</creatorcontrib><creatorcontrib>Tzankov, Alexandar</creatorcontrib><title>Immunomodulatory drugs may overcome the negative prognostic role of active Th17 axis in follicular lymphoma: evidence from the SAKK35/10 trial</title><title>British journal of haematology</title><addtitle>Br J Haematol</addtitle><subject>CD4-CD8 Ratio</subject><subject>follicular lymphoma</subject><subject>Gene Expression Profiling</subject><subject>Helper cells</subject><subject>Hematology</subject><subject>Humans</subject><subject>Immunologic Factors - administration & dosage</subject><subject>Immunomodulation</subject><subject>Kaplan-Meier Estimate</subject><subject>lenalidomide</subject><subject>Lenalidomide - administration & dosage</subject><subject>Lymphocytes T</subject><subject>Lymphoma</subject><subject>Lymphoma, Follicular - drug therapy</subject><subject>Lymphoma, Follicular - genetics</subject><subject>Lymphoma, Follicular - mortality</subject><subject>Neoplasm Proteins - biosynthesis</subject><subject>Neoplasm Proteins - genetics</subject><subject>Prognosis</subject><subject>Progression-Free Survival</subject><subject>Randomized Controlled Trials as Topic - statistics & numerical data</subject><subject>Rituximab - administration & dosage</subject><subject>RORγt</subject><subject>Th17 Cells - immunology</subject><subject>Th17 T cells</subject><subject>Tumor Microenvironment</subject><issn>0007-1048</issn><issn>1365-2141</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2020</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp1kctuEzEUhi0EoqGw4AWQJTawmMbXubArFdDSSiwoa8vjOZM42OPUnkmZl-CZcZPQBRI-C1vHnz75-EfoNSVnNK9lu1mf0bKuyidoQXkpC0YFfYoWhJCqoETUJ-hFShtCKCeSPkcnnMlcnC3Q7yvvpyH40E1OjyHOuIvTKmGvZxx2EE3wgMc14AFWerQ7wNsYVkNIozU4Bgc49Fib_c3tmlZY_7IJ2wH3wTlrsjRiN_vtOnj9AcPOdjAYwH0Mfq_9fn59zeWSEjxGq91L9KzXLsGr436Kfnz-dHtxWdx8-3J1cX5TGNGwsjC1kEK0hPGOalaVdS8bBkawVvTQVhVvBS8b0gktGq0JSFlJoyte598BQyk_RcXBm-5hO7VqG63XcVZBW3Vs_cwnUKIishGZf3fg8_R3E6RReZsMOKcHCFNSTFDGSF2yJqNv_0E3YYpDniZTXAhaUfFAvT9QJoaUIvSPT6BEPYSqcqhqH2pm3xyNU-uheyT_ppiB5QG4tw7m_5vUx6-XB-UfA_erUA</recordid><startdate>202008</startdate><enddate>202008</enddate><creator>Menter, Thomas</creator><creator>Hayoz, Stefanie</creator><creator>Zucca, Emanuele</creator><creator>Kimby, Eva</creator><creator>Dirnhofer, Stefan</creator><creator>Tzankov, Alexandar</creator><general>Blackwell Publishing Ltd</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7T5</scope><scope>H94</scope><scope>7X8</scope><scope>ADTPV</scope><scope>AOWAS</scope><scope>BTSUP</scope><orcidid>https://orcid.org/0000-0003-3078-6131</orcidid><orcidid>https://orcid.org/0000-0002-1100-3819</orcidid><orcidid>https://orcid.org/0000-0002-0847-6156</orcidid></search><sort><creationdate>202008</creationdate><title>Immunomodulatory drugs may overcome the negative prognostic role of active Th17 axis in follicular lymphoma: evidence from the SAKK35/10 trial</title><author>Menter, Thomas ; Hayoz, Stefanie ; Zucca, Emanuele ; Kimby, Eva ; Dirnhofer, Stefan ; Tzankov, Alexandar</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4926-c84544b023d1a2768f592ec42b4feb773b43690d4a49aa0e5575ca738136ec113</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2020</creationdate><topic>CD4-CD8 Ratio</topic><topic>follicular lymphoma</topic><topic>Gene Expression Profiling</topic><topic>Helper cells</topic><topic>Hematology</topic><topic>Humans</topic><topic>Immunologic Factors - administration & dosage</topic><topic>Immunomodulation</topic><topic>Kaplan-Meier Estimate</topic><topic>lenalidomide</topic><topic>Lenalidomide - administration & dosage</topic><topic>Lymphocytes T</topic><topic>Lymphoma</topic><topic>Lymphoma, Follicular - drug therapy</topic><topic>Lymphoma, Follicular - genetics</topic><topic>Lymphoma, Follicular - mortality</topic><topic>Neoplasm Proteins - biosynthesis</topic><topic>Neoplasm Proteins - genetics</topic><topic>Prognosis</topic><topic>Progression-Free Survival</topic><topic>Randomized Controlled Trials as Topic - statistics & numerical data</topic><topic>Rituximab - administration & dosage</topic><topic>RORγt</topic><topic>Th17 Cells - immunology</topic><topic>Th17 T cells</topic><topic>Tumor Microenvironment</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Menter, Thomas</creatorcontrib><creatorcontrib>Hayoz, Stefanie</creatorcontrib><creatorcontrib>Zucca, Emanuele</creatorcontrib><creatorcontrib>Kimby, Eva</creatorcontrib><creatorcontrib>Dirnhofer, Stefan</creatorcontrib><creatorcontrib>Tzankov, Alexandar</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Immunology Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>MEDLINE - Academic</collection><collection>SwePub</collection><collection>SwePub Articles</collection><collection>SwePub Editorial</collection><jtitle>British journal of haematology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Menter, Thomas</au><au>Hayoz, Stefanie</au><au>Zucca, Emanuele</au><au>Kimby, Eva</au><au>Dirnhofer, Stefan</au><au>Tzankov, Alexandar</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Immunomodulatory drugs may overcome the negative prognostic role of active Th17 axis in follicular lymphoma: evidence from the SAKK35/10 trial</atitle><jtitle>British journal of haematology</jtitle><addtitle>Br J Haematol</addtitle><date>2020-08</date><risdate>2020</risdate><volume>190</volume><issue>4</issue><spage>e258</spage><epage>e261</epage><pages>e258-e261</pages><issn>0007-1048</issn><eissn>1365-2141</eissn><cop>England</cop><pub>Blackwell Publishing Ltd</pub><pmid>32525232</pmid><doi>10.1111/bjh.16876</doi><tpages>3</tpages><orcidid>https://orcid.org/0000-0003-3078-6131</orcidid><orcidid>https://orcid.org/0000-0002-1100-3819</orcidid><orcidid>https://orcid.org/0000-0002-0847-6156</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0007-1048 |
| ispartof | British journal of haematology, 2020-08, Vol.190 (4), p.e258-e261 |
| issn | 0007-1048 1365-2141 |
| language | eng |
| recordid | cdi_swepub_primary_oai_swepub_ki_se_470594 |
| source | MEDLINE; Wiley Free Content; Wiley Online Library All Journals |
| subjects | CD4-CD8 Ratio follicular lymphoma Gene Expression Profiling Helper cells Hematology Humans Immunologic Factors - administration & dosage Immunomodulation Kaplan-Meier Estimate lenalidomide Lenalidomide - administration & dosage Lymphocytes T Lymphoma Lymphoma, Follicular - drug therapy Lymphoma, Follicular - genetics Lymphoma, Follicular - mortality Neoplasm Proteins - biosynthesis Neoplasm Proteins - genetics Prognosis Progression-Free Survival Randomized Controlled Trials as Topic - statistics & numerical data Rituximab - administration & dosage RORγt Th17 Cells - immunology Th17 T cells Tumor Microenvironment |
| title | Immunomodulatory drugs may overcome the negative prognostic role of active Th17 axis in follicular lymphoma: evidence from the SAKK35/10 trial |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-12T06%3A11%3A02IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_swepu&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Immunomodulatory%20drugs%20may%20overcome%20the%20negative%20prognostic%20role%20of%20active%20Th17%20axis%20in%20follicular%20lymphoma:%20evidence%20from%20the%20SAKK35/10%20trial&rft.jtitle=British%20journal%20of%20haematology&rft.au=Menter,%20Thomas&rft.date=2020-08&rft.volume=190&rft.issue=4&rft.spage=e258&rft.epage=e261&rft.pages=e258-e261&rft.issn=0007-1048&rft.eissn=1365-2141&rft_id=info:doi/10.1111/bjh.16876&rft_dat=%3Cproquest_swepu%3E2412208629%3C/proquest_swepu%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2434417149&rft_id=info:pmid/32525232&rfr_iscdi=true |